Evidence map›Paper›PMID 41512122›Full record

ArticleJournal of the American Chemical Society2026

Unified Synthesis Platform for 1,2,3-Trisubstituted Cyclopentadienyl Ligands Decouples Sterics from Electronics.

Bram Van Den Bossche, Nicolai Cramer

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bram Van Den BosscheLaboratory of Asymmetric Catalysis and Synthesis (LCSA), Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0009-0000-2139-2785
Nicolai CramerLaboratory of Asymmetric Catalysis and Synthesis (LCSA), Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-5740-8494

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclopentadienyl (Cp) ligands are a cornerstone of coordination chemistry and transition-metal catalysis. Their tuning profoundly influences the chemical and biological reactivity, the induced selectivity, and the stability of the corresponding metal complexes. However, compared to phosphines for instance, the accessible chemical space of Cps is rather narrow, exhibiting major limitations regarding the nature, pattern, and number of Cp substituents. A unified synthetic strategy toward partially substituted Cps bearing diverse functionalities and closing gaps in chemical space is highly desirable. Herein, we report a streamlined general strategy to prepare 1,2,3-trisubstituted cyclopentadienes (1,2,3-Cps) from a central inexpensive precursor. Operationally straightforward reactions and purifications ensure scalable sequences. The robust and versatile synthesis platform opens access to underexplored Cp substitution patterns - including flexible incorporation of diverse alkyls, aryls, and previously elusive or rare functionalities such as halogens, chalcogens, and alkynes - with a profound ligand tunability and decoupling of sterics from electronics. The complexation ability with a selection of catalytically relevant early and late transition metals was demonstrated, and parametrization of the Cps with respect to their stereoelectronic environment was performed via the corresponding Cp rhodium phosphite species. In exemplary selected benchmark catalytic transformations, the cobalt and rhodium complexes directly outperformed classical Cp ligands with respect to individual reactivity, regioselectivity, and catalyst loading. Regarding catalytic turnover, a 1,2,3-Cp cobalt complex achieved an attractive turnover number (TON) of 180 for a benchmark C-H annulation.

Identifiers

PMID41512122
PMCPMC12856903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.